Extrait

The primary objective is to estimate the progression-free survival (PFS) for the combination of pemetrexed plus cisplatin plus cetuximab followed by optional pemetrexed plus cetuximab maintenance therapy.

Critère d'inclusion

• Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Liens

• ictrp
• ictrp
• euctr
• euctr
• euctr
• ictrp
• ictrp
• ictrp
• euctr
• euctr